welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
John L. Jefferies, MD, MPH, FACC, FAHA, FHFSA
University of Tennessee Health Science Center
A312 Coleman Building
956 Court Avenue
Memphis, Tennessee, United States
In 2018, John L. Jefferies has been appointed the Jay M. Sullivan Endowed Chair in Cardiovascular Medicine and Chief of Cardiology at the University of Tennessee Health Science Center (UTHSC). He has also been named co-director for UT Methodist Institute for Cardiovascular Science.
Dr. Jefferies graduated from UT Knoxville with a degree in microbiology in 1992 and acquired his medical degree from UTHSC in 1996. He then completed an internship and residency in internal medicine and pediatrics at the University of Kentucky followed by adult and pediatric cardiology (combined) training at Baylor College of Medicine in Houston, TX. Dr. Jefferies has served for more than eight years at the University of Cincinnati College of Medicine and Cincinnati Children’s, where he was an associate professor of adult cardiovascular disease and pediatric cardiology from 2010-2015, professor of adult cardiovascular disease and pediatric cardiology from 2015-2018, and professor of human genetics from 2015-2018.
His research interests include novel gene discovery for various forms of cardiomyopathy, quality-of-life research in cardiomyopathy and heart failure, cardio-oncology, cardiac care in genetic syndromes, and novel drug investigation in heart failure.
other Duchenne content
Duchenne Pulmonary Awareness: C-PAP/BiPAPhttps://www.youtube.com/watch?v=_EuyErNY...
A Randomized, Double-blind, Placebo-controlled Study of SRP-9001 for Duchenne Muscular Dystrophy (DMD)The purpose of this study is to evaluate...
Results at 96 Weeks of a Phase IIb Extension Study of the Exon-Skipping Drug Eteplirsen in Patients with Duchenne Mu...Objective: The objective of this study ...
Ryan Benton Discusses Stem Cell Therapy for Duchenne Muscular Dystrophyhttps://www.youtube.com/watch?v=K94yWLJf...
Sarepta Announces Clinical Hold Lifted for its Duchenne Muscular Dystrophy Micro-dystrophin Gene Therapy ProgramSarepta Therapeutics, Inc., a commercial...
Duchenne Muscular Dystrophy – Information for CarriersMuscular dystrophies (MD) are common neu...
Study of Eteplirsen in Young Patients With DMD Amenable to Exon 51 SkippingThis is a multicenter, open-label, dose-...